Alzheimer’s Breakthrough Drugs: Hype, Hope, and Hard Truths

Alzheimer’s Drugs Under Scrutiny: Are They Worth It?

The arrival of drugs like donanemab and lecanemab was hailed as a turning point in Alzheimer’s research. For the first time, treatments showed they could slow the pace of cognitive decline by targeting beta amyloid, the sticky protein that builds up between brain cells. Yet, new analysis suggests the reality may be far less groundbreaking than the headlines promised.

The Cochrane Collaboration reviewed 17 studies involving more than 20,000 volunteers. Their conclusion: while these drugs do slow Alzheimer’s progression, the effect is too small to make a meaningful difference in patients’ daily lives. This finding has ignited fierce debate among scientists, with some praising the honesty of the report and others condemning it as fundamentally flawed.

One major concern is cost. In the UK, the NHS has refused to fund these treatments, leaving private patients facing bills of around £90,000 for an 18‑month course. For most families, that price tag is simply out of reach. Even if affordable, the drugs come with risks, including brain swelling and bleeding, and require regular infusions every two to four weeks.

Experts are divided. Professor Edo Richard, a neurologist in the Netherlands, warns patients not to expect real benefits, stressing the importance of avoiding false hope. Critics like Professor Robert Howard at UCL argue that the hype has unfairly raised expectations among families. Meanwhile, supporters such as Professor Bart De Strooper insist newer antibodies do deliver modest but genuine improvements, and dismiss the review as misleading.

The Alzheimer’s Society urges caution, calling for nuanced interpretation rather than sweeping judgments. They highlight decades of pioneering research that should not be dismissed outright. At the same time, many researchers believe the future lies in exploring alternative approaches, such as targeting brain inflammation.

For now, access remains limited. The NHS continues to review evidence, weighing not only clinical outcomes but also the burden on unpaid carers. Until then, families are left with difficult choices: whether to pursue costly private treatment or wait for more effective, affordable options.

The debate over Alzheimer’s drugs reflects a broader truth—science rarely delivers simple answers. Progress is real, but the path to meaningful change for dementia patients is still unfolding.